Gain Therapeutics Reports Promising Phase 1b Data for Parkinson’s Drug, Eyes Phase 2 Start — Gain Therapeutics, Inc.

Event summary

Gain Therapeutics reported stable MDS-UPDRS scores and 81% reduction in GluSph levels in Phase 1b extension study for GT-02287.
Company expects FDA IND clearance for GT-02287 in Q2 2026 and Phase 2 trial initiation in Q3 2026.
GT-04686, a new GCase allosteric modulator, showed promising preclinical results and is ready for IND-enabling studies.
Q1 2026 net loss was $0.13 per share, down from $0.16 per share in Q1 2025, with cash position at $16.5 million.

The big picture

Gain Therapeutics is positioning itself as a leader in allosteric small molecule therapies for neurodegenerative diseases, with GT-02287 representing a potential paradigm shift in Parkinson’s treatment from symptom management to disease modification. The company’s proprietary Magellan™ platform continues to yield promising candidates, but its ability to execute on regulatory and clinical milestones will be critical for long-term success in a competitive biotech landscape.

What we're watching

Regulatory Timing: Whether Gain can secure FDA IND clearance for GT-02287 in Q2 2026 as planned, clearing the path for Phase 2 initiation.
Clinical Efficacy: The durability of MDS-UPDRS score stability and biomarker reductions in the Phase 1b extension study, to be presented at the 3rd International GBA1 Meeting.
Pipeline Progression: The pace at which GT-04686 advances through IND-enabling studies, potentially expanding Gain’s pipeline for Parkinson’s and other neurological disorders.